Specialty Generics Market by Product Type, Distribution Channel, End User 2024-2032
                     Global Specialty Generics 
Market Research and 
Forecast Report 2024-
2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
In ternat ional  Market  Analys is  Research and Consul t ing Group is  a leading adv iser  on management  
s t rategy and market  research wor ldwide.  We par tner  wi th c l ients  in  a l l  regions and indust ry  
vert ica ls  to  ident i fy  thei r  h ighest -value oppor tuni t ies,  address thei r  most  cr i t ica l  chal lenges,  and 
t ransform thei r  bus inesses.
IMARC’s in format ion products  inc lude major market ,  sc ient i f ic ,  economic and technological  
developments  for  bus iness leaders  in  pharmaceut ica l ,  indust r ia l ,  and h igh technology 
organizat ions.  Market  forecasts  and indust ry  analys is  for  b iotechnology,  advanced mater ia ls ,  
chemicals ,  food and beverage,  t ravel  and tour ism, nanotechnology and novel  process ing methods 
are at  the top of  the company’s  exper t ise.
IMARC’s ta i lored approach combines unfathomable ins ight  in to the dynamics o f  companies and 
markets wi th c lose cooperat ion at  a l l  levels  of  the c l ient  organizat ion.  This ensures that  our  c l ients 
achieve unmatchable compet i t ive advantage,  bui ld  more pro f ic ient  organizat ions,  and secure 
las t ing resul ts .
According to the la test  repor t  by IMARC Group,  t i t led  "Special ty 
Generics Market:  Global  Industry Trends,  Share,  S ize,  Growth,  
Opportunity  and Forecast  2024-2032,"  the g lobal  spec ia l ty  gener ics  
Report market  s ize reached US$ 74.7  B i l l ion in  2023.
Spec ia l ty  gener ics  refer  to  of f -patented drugs which are used to target  
Highlight and chron ic  or  complex hea l th  cond i t ions.  These drugs requ i re  spec ia l  handl ing,  moni tor ing or  admin is t rat ion and general ly  need pr ior  
author iza t ion to order  them. Nowadays,  spec ia l ty  gener ics  are  ga in ing 
Description immense popular i ty  as they are  u t i l i zed to t reat  rare chronic  d iseases 
such as cancer,  HIV AIDS,  rheumato id ar thr i t is  and hemophi l ia .
Request  for  a  PDF sample of  th is report:  
ht tps: / /www. imarcgroup.com/spec ia l ty -gener ics-market / requestsample
Report Description
G l ob a l  Sp ec i a l t y  G ene r i cs  M ar ke t  T rend s :
The  i nc r eas in g  de m an d  f o r  s pec ia l t y  d r ug s  ha s  e ncou r aged  t he  go ve r n m en t s  o f  va r i ous  cou n t r i e s  t o  r egu la t e  a nd  p r ov id e  
suppo r t i ng  p o l i c i e s  f o r  t he  p r oduc t i on  o f  spec ia l t y  gen e r i cs .  B es ide s  t h i s ,  un l i k e  n ew ly  pa t e n t ed  s pec ia l t y  d r ugs ,  
spec i a l t y  gen e r i cs  a r e  l ess  ex pens iv e  t o  deve lo p  a nd  m an u f ac t u r e  as  t hey  do  no t  hav e  t o  un de r g o  a ny  c l i n i ca l  t r i a l s  a nd  
app r o va l  be f o r e  e n t e r i ng  t he  m ar ke t .  As  a  r esu l t ,  t hes e  p r od uc t s  i nv o l ve  l ow  r i sk  an d  h igh  m ar g ins  as  com par ed  t o  new ly  
pa t e n t ed  d r ug s  wh ic h  us ua l l y  t ake  t h r ee  t o  f ou r  yea r s  f o r  p r o duc t  dev e lopm en t  a nd  a pp r ov a l .  
M or e ove r ,  m an u f ac t u r e r s  a r e  in vo l ve d  i n  r esea r ch  and  d eve lop m en t  ( R&D)  t o  c r ea t e  n ew and  i nn ova t i v e  spec ia l t y  d r u g  
f o r m u la t i o ns  t h a t  a r e  m o r e  e f f i c i en t  and  cos t - e f f ec t i v e  as  c om p ar ed  t o  t h e i r  b r ande d  cou n t e r p a r t s .  Add i t i ona l l y ,  s eve r a l  
com pan ies  a r e  engag ing  i n  m e r ge r s  a nd  acq u is i t i on s  ( M &A )  t o  exp and  t he i r  s pec ia l t y  gene r i cs  ca pac i t i e s .  Fo r  i ns t ance ,  
A l voge n ,  a  pha r m ac eu t i ca l  com pan y ,  ac qu i r e d  Cou n t y  L ine  Pha r m aceu t i ca ls  t ha t  i s  i nvo l ved  i n  t he  dev e lopm en t  o f  
spec i a l t y  g ene r i cs .
Look i ng  f o rw a rd ,  t he  mar ke t  va l ue  i s  p r o j ec t ed  t o  rea ch  US$  1 72 . 5  B i l l i o n  by  2032 ,  exh i b i t i ng  a  CAG R  o f  9 . 4%  
dur i ng  20 24 - 2 032 .
V i ew  Repo r t  T O C,  F i g ures  and  T ab l e s :  h t t ps : / / w w w . i mar cgrou p . com / s pec i a l t y - g ener i cs - m ark e t
Breakup by Route of Administration:
• In jectables
• Oral
• Others
 
Breakup by Indication:
Report • Oncology
• Autoimmune Diseases
Segmentation
• Infect ious Diseases
• Others
Breakup by Distribution channel:
• Retai l  Pharmacies
• Specia l ty Pharmacies
• Hospital  Pharmacies
Breakup by Region:
• North America
• Europe
Report • Asia-Pacifi c
• Latin America
Segmentation • Middle East and Afr ica
• Teva Pharmaceuticals Industr ies
• Akorn, Inc.
• Mylan N.V.
Competitive 
• Mall inckrodt
Landscape • Sandoz International GmbH
with Key • Pfi zer, Inc.
• Sun Pharmaceutical  Industries Ltd.
Players
• Valeant Pharmaceuticals
• Apotex Corp.
• Endo International  plc
What is the size of the global specialty generics 
market?
What are the key factors driving the global 
specialty generics market?
What has been the impact of COVID-19 on the 
Key global specialty generics market?
Questions What is the breakup of the global specialty generics market based on the route of 
administration?
Answered in 
What is the breakup of the global specialty 
the Report generics market based on the indication?
What is the breakup of the global specialty 
generics market based on the distribution channel?
What are the key regions in the global specialty 
generics market?
Who are the key players/companies in the global 
specialty generics market?
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
Table of     2 . 4     M a r k e t  E s t i m a t i o n        2 . 4 . 1     B o t t o m - U p  A p p r o a c h
        2 . 4 . 2     T o p - D o w n  A p p r o a c h
    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
Contents 4    G l o b a l  S p e c i a l t y  G e n e r i c s  M a r k e t :  I n t r o d u c t i o n5    W h y  a r e  S p e c i a l t y  G e n e r i c s  S o  L u c r a t i v e ?
6    G l o b a l  S p e c i a l t y  G e n e r i c s  M a r k e t
    6 . 1     M a r k e t  O v e r v i e w
    6 . 2     M a r k e t  P e r f o r m a n c e
    6 . 3     I m p a c t  o f  C O V I D - 1 9
    6 . 4     M a r k e t  B r e a k u p  b y  R o u t e  o f  A d m i n i s t r a t i o n
    6 . 5     M a r k e t  B r e a k u p  b y  I n d i c a t i o n
    6 . 6     M a r k e t  B r e a k u p  b y  D i s t r i b u t i o n  C h a n n e l
    6 . 7     M a r k e t  B r e a k u p  b y  R e g i o n
    6 . 8     M a r k e t  F o r e c a s t
    6 . 9     S W O T  A n a l y s i s
        6 . 9 . 1     O v e r v i e w
        6 . 9 . 2     S t r e n g t h s
        6 . 9 . 3     W e a k n e s s e s
        6 . 9 . 4     O p p o r t u n i t i e s
        6 . 9 . 5     T h r e a t s
       
 6 . 1 0     V a l u e  C h a i n  A n a l y s i s
    6 . 1 1     P o r t e r s  F i v e  F o r c e s  A n a l y s i s
        6 . 1 1 . 1     O v e r v i e w
        6 . 1 1 . 2     B a r g a i n i n g  P o w e r  o f  B u y e r s
        6 . 1 1 . 3     B a r g a i n i n g  P o w e r  o f  S u p p l i e r s
        6 . 1 1 . 4     D e g r e e  o f  C o m p e t i t i o n
        6 . 1 1 . 5     T h r e a t  o f  N e w  E n t r a n t s
        6 . 1 1 . 6     T h r e a t  o f  S u b s t i t u t e s
    6 . 1 2     K e y  M a r k e t  D r i v e r s  a n d  S u c c e s s  F a c t o r s
7    M a r k e t  B r e a k u p  b y  R o u t e  o f  A d m i n i s t r a t i o n
Table of     7 . 1     I n j e c t a b l e        7 . 1 . 1     M a r k e t  T r e n d s
        7 . 1 . 2     M a r k e t  F o r e c a s t
    7 . 2     O r a l
Contents         7 . 2 . 1     M a r k e t  T r e n d s        7 . 2 . 2     M a r k e t  F o r e c a s t
    7 . 3     O t h e r s
        7 . 3 . 1     M a r k e t  T r e n d s
        7 . 3 . 2     M a r k e t  F o r e c a s t
8    M a r k e t  B r e a k u p  b y  I n d i c a t i o n
    8 . 1     O n c o l o g y
        8 . 1 . 1     M a r k e t  T r e n d s
        8 . 1 . 2     M a r k e t  F o r e c a s t
    8 . 2     A u t o i m m u n e  D i s e a s e s
        8 . 2 . 1     M a r k e t  T r e n d s
        8 . 2 . 2     M a r k e t  F o r e c a s t
    8 . 3     I n f e c t i o u s  D i s e a s e s
        8 . 3 . 1     M a r k e t  T r e n d s
        8 . 3 . 2     M a r k e t  F o r e c a s t     
F o r  m o r e  i n f o r m a t i o n ,  v i s i t :  
h t t p s : / / w w w. im a rcg ro u p . co m / s p e c i a l t y - g en e r i c s - m a r ke t / t o c
Disclaimer
© 2023  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
TELEPHONE: +1-631-791-1145 
E-MAIL: [email protected]